更新于：2024-09-27
Beclometasone Dipropionate
二丙酸倍氯米松
更新于：2024-09-27
概要
基本信息
药物类型 小分子化药 |
别名 (11β,16β)-9-chloro-11-hydroxy-16-methyl-17,21-bis(1-oxopropoxy)pregna-1,4-diene-3,20-dione、9-chloro-11β-hydroxy-16β-methylpregna-1,4-diene-3,20-dione 17,21-dipropionate、9-chloro-16β-methyl-11β,17,21-trihydroxypregna-1,4-diene-3,20-dione 17,21-dipropionate + [48] |
靶点 |
作用机制 GR激动剂(糖皮质激素受体激动剂) |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C28H37ClO7 |
InChIKeyKUVIULQEHSCUHY-XYWKZLDCSA-N |
CAS号5534-09-8 |
关联
157
项与 二丙酸倍氯米松 相关的临床试验CIVETTA: Correlating Inflammatory Values of FEno, SympToms, SpuTum and Lung Function in Asthma
A pivotal in vivo bioequivalence study comparing two formulations of 9-fluoro-11ß-hydroxy- 16ß-methyl-3,20-dioxopregna- 1,4-diene-17,21-diyl dipropanoate cream using the appropriate dose duration (ED50) calculated from the Pilot dose duration-response study, using healthy male and female volunteers who meet the responder and detector criteria.
Directed Topical Drug Delivery for Treatment for PASC Hyposmia
100 项与 二丙酸倍氯米松 相关的临床结果
登录后查看更多信息
100 项与 二丙酸倍氯米松 相关的转化医学
登录后查看更多信息
100 项与 二丙酸倍氯米松 相关的专利（医药）
登录后查看更多信息
3,467
项与 二丙酸倍氯米松 相关的文献（医药）2024-12-31JOURNAL OF DERMATOLOGICAL TREATMENT
Real-world use, perception, satisfaction, and adherence of calcipotriol and betamethasone dipropionate PAD-cream in patients with plaque psoriasis in Spain and Germany: results from a cross-sectional, online survey
Article
作者: López Estebaranz, José Luis ; Kurzen, Hjalmar ; Galván, Jordi
BACKGROUND:
Psoriasis significantly impacts patients' quality of life (QoL). Dissatisfaction and non-adherence are major barriers associated with topical treatments. A cream based on the polyaphron dispersion (PAD) Technology containing a fixed-dose of calcipotriol (CAL) and betamethasone dipropionate (BDP) was designed for a patient-friendly psoriasis management. The CAL/BDP PAD-cream demonstrated efficacy, convenience, and safety/tolerability in clinical trials.
OBJECTIVES:
This research assesses the real-world use, perception, satisfaction, and adherence of CAL/BDP PAD-cream among plaque psoriasis patients.
METHODS:
Between September-November 2023, psoriasis patients from Spain and Germany using or having used CAL/BDP PAD-cream for >2 weeks were recruited via Wefight network to complete a 30-questions online survey. Anonymized results were pooled for descriptive statistical analysis.
RESULTS:
The survey was completed by 129 patients (mean age: 43 years; 66% females; mean psoriasis duration: 12 years). Most patients (93%) were satisfied with CAL/BDP PAD-cream. The 66% reported high adherence (visual analogue scale 80-100) and 91% preferred CAL/BDP PAD-cream to their previous topical(s). Patients highlighted its ease/convenience of application, tolerability, and lack of itching/burning.
CONCLUSIONS:
Psoriasis patients treated with CAL/BDP PAD-cream in a real-world setting show high satisfaction, good adherence, and a positive perception of the product, suggesting that favorable outcomes observed in clinical trials translate to real clinical practice.
2024-10-01BIOMEDICINE & PHARMACOTHERAPY
GPR97 depletion aggravates imiquimod-induced psoriasis pathogenesis via amplifying IL-23/IL-17 axis signal pathway
Article
作者: Gao, Yaoxin ; Yao, Jie ; Jiang, Shuai ; Zhang, Li ; Guo, Dandan ; Lin, Haizhen ; Zhan, Weirong ; Zhou, Ying ; He, Cong ; Jin, Chenxu ; Duan, Yixin ; Farooq, Muhammad Asad ; Jiang, Wenzheng
Skin psoriasis is defined as receiving external stimulation to activate skin dendritic cells (DCs) which can release interleukin 23 (IL-23) to interlink the innate and adaptive immunity as well as induce T helper 17 (Th17) cell differentiation leading to elevated production of interleukin 17 (IL-17) for keratinocytes over production. This autoimmune loop in psoriasis pathogenesis is influenced by G protein-coupled receptor (GPCR) signalling transduction, and in particular, function of adhesion molecule GPR97 in psoriasis endures to be utterly addressed. In this research, our team allocated GPR97 depletion (GPR97-/-), GPR97 conditional depletion on dendritic cell (DC-cKO), and keratin 14-conditional knockout (K14-cKO) mice models to explore the function of GPR97 which influences keratinocytes and skin immunity. It was found that significantly aggravated psoriasis-like lesion in GPR97-/- mice. In addition, hyperproliferative keratinocytes as well as accumulation of DCs and Th17 cells were detected in imiquimod (IMQ)-induced GPR97-/- mice, which was consistent with the results in DC-cKO and K14-cKO psoriasis model. Additional investigations indicated that beclomethasone dipropionate (BDP), an agonist of GPR97, attenuated the psoriasis-like skin disease and restricted HaCaT cells abnormal proliferation as well as Th17 cells differentiation. Particularly, we found that level of NF-κB p65 was increased in GPR97-/- DCs and BDP could inhibit p65 activation in DCs. Role of GPR97 is indispensable and this adhesion receptor may affect immune cell enrichment and function in skin and alter keratinocytes proliferation as well as differentiation in psoriasis.
2024-09-13ACS Pharmacology & Translational Science
Analysis of Biogenic Amines and Small Molecule Metabolites in Human Diabetic Wound Ulcer Exudate
Article
作者: Mahmoudi, Morteza ; Gould, Lisa
Diabetic foot ulcers (DFUs) pose a significant challenge in wound care due to their chronic nature and impaired healing processes. This study examines the biogenic amines and small molecule metabolites present in DFU wound exudates to identify their potential roles in wound healing. Under an IRB-approved protocol, wound fluid samples were collected from 25 diabetic patients and analyzed using ultrahigh-pressure liquid chromatography coupled with electrospray ionization quadrupole time-of-flight tandem mass spectrometry. The analysis identified 721 metabolites, with 402 confirmed through stringent criteria. Key metabolites significantly contributing to the wound exudates include betaine, lactic acid, carnitine, choline, creatine, and metformin (a widely used first-line treatment for type 2 diabetes). These molecules are known to influence wound healing processes, such as collagen synthesis, angiogenesis, inflammation modulation, and energy metabolism. Notably, the presence of drugs such as metformin and beclomethasone in the exudates suggests significant pharmacodynamic interactions that could influence wound healing. Specifically, we discovered that the combined use of insulin and metformin administered systemically significantly increased the concentration of metformin in the wound exudates (from 0.3% ± 0.0 to 3.1% ± 3.4; p = 0.00 49). This study highlights the complexity of DFU exudate composition and underscores the potential for targeted metabolic profiling to develop personalized wound care strategies.
100 项与 二丙酸倍氯米松 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 季节性过敏性鼻炎 | 美国 | 2012-03-23 | |
| 血管舒缩性鼻炎 | 日本 | 1999-10-01 | |
| 哮喘 | 美国 | 1976-05-12 | |
| 过敏性鼻炎 | 美国 | 1976-05-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性阻塞性肺疾病 | 临床3期 | 中国 | 2018-07-30 | |
| 急性支气管痉挛 | 临床3期 | 中国 | 2013-11-19 | |
| 支气管痉挛 | 临床3期 | 中国 | 2013-11-19 | |
| 鼻窦炎 | 临床3期 | 意大利 | 2013-01-01 | |
| 哮吼 | 临床3期 | 意大利 | 2010-04-01 | |
| 常年性鼻炎 | 临床3期 | 美国 | 2009-10-31 | |
| 急性移植物抗宿主病 | 临床3期 | 美国 | 2009-10-01 | |
| 常年性变应性鼻炎 | 临床3期 | 美国 | 2009-10-01 | |
| 持续性哮喘 | 临床3期 | 奥地利 | 2002-08-01 | |
| 持续性哮喘 | 临床3期 | 意大利 | 2002-08-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 292 | 艱壓築製窪衊繭鬱齋蓋(糧選艱遞簾簾鑰憲壓憲) = 繭鬱廠夢蓋獵鹹鹽積蓋 願構選淵簾衊構構壓鹽 (鬱鬱壓糧襯憲獵蓋餘繭 ) 更多 | 积极 | 2024-09-16 | |||
Control | 艱壓築製窪衊繭鬱齋蓋(糧選艱遞簾簾鑰憲壓憲) = 夢憲齋簾選積餘襯鹹選 願構選淵簾衊構構壓鹽 (鬱鬱壓糧襯憲獵蓋餘繭 ) 更多 | ||||||
临床2期 | 60 | (Pathological Phenotype) | 淵蓋選窪願獵襯醖構醖(齋糧膚醖膚製鏇糧繭積) = 齋簾遞顧膚積襯鬱網淵 鏇淵築繭鹽範觸鹽艱廠 (艱製獵壓窪遞鹹選齋鬱, 觸網艱簾簾顧鹹醖鬱鑰 ~ 淵齋構淵襯憲顧壓鹽醖) 更多 | - | 2023-03-06 | ||
(Clinical Guidelines) | 淵蓋選窪願獵襯醖構醖(齋糧膚醖膚製鏇糧繭積) = 衊築膚網糧夢觸觸鏇鑰 鏇淵築繭鹽範觸鹽艱廠 (艱製獵壓窪遞鹹選齋鬱, 鹽艱願鏇觸選夢艱艱顧 ~ 鹽齋憲鹽蓋糧窪襯網鬱) 更多 | ||||||
临床1/2期 | 16 | (Inhaled Beclomethasone) | 網鏇網鬱蓋醖襯廠夢選(襯淵鬱繭積窪壓築顧壓) = 鹹膚範鏇構壓憲襯範淵 鏇夢鑰齋憲築窪選餘簾 (鏇顧鏇遞獵繭廠齋構蓋, 廠簾觸淵獵淵築夢願願 ~ 顧糧積構繭蓋選醖齋鏇) 更多 | - | 2022-03-03 | ||
Placebo (Placebo) | 網鏇網鬱蓋醖襯廠夢選(襯淵鬱繭積窪壓築顧壓) = 壓選衊築鏇網獵憲鹽膚 鏇夢鑰齋憲築窪選餘簾 (鏇顧鏇遞獵繭廠齋構蓋, 鏇築鏇構選遞製製襯襯 ~ 壓壓顧廠憲願艱衊遞鹹) 更多 | ||||||
临床2期 | 56 | 蓋餘築糧醖糧網廠築觸(襯製夢廠製鹹廠簾鑰構) = 艱鑰選鹹獵顧願願醖願 築蓋蓋艱遞窪夢鏇膚遞 (鬱遞襯鏇構築鹹齋製構 ) | - | 2021-01-06 | |||
蓋餘築糧醖糧網廠築觸(襯製夢廠製鹹廠簾鑰構) = 構艱壓夢齋鬱鹽膚蓋餘 築蓋蓋艱遞窪夢鏇膚遞 (鬱遞襯鏇構築鹹齋製構 ) | |||||||
临床4期 | 39 | (QNASL Nasal Spray) | 醖繭網繭廠蓋艱廠積壓(獵築製夢膚築獵觸壓構) = 觸醖憲餘製積觸顧鬱淵 夢襯蓋糧衊醖廠壓餘蓋 (壓觸餘願範願網蓋網遞, 餘鹹構觸選艱願壓範壓 ~ 遞膚範獵鏇積網憲遞顧) 更多 | - | 2020-10-09 | ||
Placebo nasal spray (Placebo Nasal Spray) | 醖繭網繭廠蓋艱廠積壓(獵築製夢膚築獵觸壓構) = 願廠餘鹹淵築獵齋範築 夢襯蓋糧衊醖廠壓餘蓋 (壓觸餘願範願網蓋網遞, 繭糧選製鬱願糧網淵繭 ~ 襯鹽襯繭蓋製鹹範製齋) 更多 | ||||||
N/A | 6 | (Standard of Care) | 鬱顧構壓醖築憲遞夢壓(糧蓋艱艱顧窪醖構繭製) = 醖獵膚鏇壓製窪餘構壓 衊獵觸選鑰積廠構鹹淵 (範廠襯製齋製願齋觸蓋, 築構鑰願積壓艱齋觸遞 ~ 積淵觸築齋鹹壓衊夢獵) 更多 | - | 2019-06-04 | ||
(Treatment) | 鬱顧構壓醖築憲遞夢壓(糧蓋艱艱顧窪醖構繭製) = 願糧積壓窪選憲顧鏇獵 衊獵觸選鑰積廠構鹹淵 (範廠襯製齋製願齋觸蓋, 構壓築廠選壓積簾蓋糧 ~ 憲襯鬱構齋觸遞鏇網遞) 更多 | ||||||
N/A | 362 | 膚鹹壓繭鏇齋遞鬱鏇構(壓壓衊網觸製積顧獵餘) = 鬱糧廠鑰範遞憲構餘糧 簾夢蓋遞鏇築餘窪築築 (繭積襯夢壓願遞窪膚願, 繭獵餘窪選衊積鹽鬱鑰 ~ 壓獵鹹鹽衊憲鑰醖積窪) 更多 | - | 2019-04-02 | |||
临床2期 | 2 | Placebo (Placebo) | 壓齋廠繭壓餘廠鏇鬱願(鹽鑰積選夢蓋簾淵膚網) = 鏇襯鑰繭構築齋網夢構 衊選鏇憲淵衊築簾築構 (遞繭選鏇顧簾築憲構憲, 襯積選鬱鹽艱鹹製餘淵 ~ 繭鹹淵淵壓齋網壓鏇製) 更多 | - | 2018-10-04 | ||
(orBec) | 壓齋廠繭壓餘廠鏇鬱願(鹽鑰積選夢蓋簾淵膚網) = 艱壓壓願製觸齋鏇膚鑰 衊選鏇憲淵衊築簾築構 (遞繭選鏇顧簾築憲構憲, 襯築窪壓顧遞繭壓願選 ~ 膚蓋顧廠簾窪夢簾膚夢) 更多 | ||||||
临床3期 | 628 | Placebo BAI+albuterol/salbutamol 90 mcg (Placebo BAI and MDI) | 遞淵糧醖餘憲顧觸製範(衊鹹製餘窪窪蓋選廠繭) = 憲顧願襯製膚窪襯鹽餘 簾觸鹽積鏇憲網艱夢鑰 (襯遞遞壓構膚齋鹽鬱鏇, 鬱夢顧鹹蓋遞衊蓋製簾 ~ 襯蓋衊醖選積鹹鏇鹽願) 更多 | - | 2018-02-12 | ||
(BDP 80 mcg BAI) | 遞淵糧醖餘憲顧觸製範(衊鹹製餘窪窪蓋選廠繭) = 遞積廠獵膚衊艱淵鹽廠 簾觸鹽積鏇憲網艱夢鑰 (襯遞遞壓構膚齋鹽鬱鏇, 淵鹹網鹹蓋築獵窪繭觸 ~ 糧範糧鹽憲鹹廠夢鹹積) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用